Commutee

Biogen easily tops Street estimates on Spinraza sales, raises forecast

July 24, 2018 by  
Filed under News

Biogen Inc reported far better-than-expected second quarter profit on Tuesday, driven by strong demand of its Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast.


Source: Reuters Business News

Comments are closed.